Erratum: Ovarian cancer cells, not normal cells, are damaged by mirk/dyrk1b kinase inhibition(International Journal of Cancer (2013) 132:10 (2258-2269) 10.1002/ijc.27917);Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition

International Journal of Cancer

Volumn 132, Issue 10, 2013, Pages 2258-2269

  Hu, Jing ^a   Deng, Holly ^a   Friedman, Eileen A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Dyrk1B; Mirk; ovarian cancer; quiescence; ROS

Indexed keywords

ACETYLCYSTEINE; CALSENILIN; CASPASE 3; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DYRK1B KINASE; HISTONE H2AX; MIRK KINASE; MYELIN BASIC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE; PROTEIN P130; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR E2F4; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; DIPLOIDY; DOSE RESPONSE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR MICROENVIRONMENT; UBIQUITINATION; UPREGULATION;

EID: 84874936048     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29555     Document Type: Erratum

References (30)

1. Tejedor F, Zhu X, Kaltenbach E, et al. Minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron 1995; 14: 287-301.
2. Kentrup H, Becker W, Heukelbach J, et al. Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII. J Biol Chem 1996; 271: 3488-95.
3. Becker W, Weber Y, Wetzel K, et al. Sequence characteristics, subcellular localization and substrate specificity of dyrk-related kinases, a novel family of dual specificity protein kinases. J Biol Chem 1998; 273: 25893-902.
4. Jin K, Lim S, Mercer SE, et al. The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling. J Biol Chem 2005; 280: 42097-105.
5. Jin K, Park S-J, Ewton D, et al. The survival kinase Mirk/dyrk1B is a downstream effector of oncogenic K-ras. Cancer Res 2007; 67: 7247-55.
6. Jin K, Ewton D, Park S, et al. Mirk regulates the exit of colon cancer cells from quiescence. J Biol Chem 2009; 284: 22916-25.
7. Lauth M, Bergstrom A, Shimokawa T, et al. DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol 2010; 17: 718-25.
8. Lee K, Deng X, Friedman E,. Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. Cancer Res 2000; 60: 3631-7.
9. Hu J, Nakhla H, Friedman E,. Mirk/dyrk1B and p130/Rb2 mediate quiescence in ovarian cancer cells. Int J Cancer 2011; 129: 307-18.
10. Kuuselo R, Savinainen K, Azorsa DO, et al. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res 2007; 67: 1943-9.
11. Thompson FH, Nelson MA, Trent JM, et al. Amplification of 19q13.1-q13.2 sequences in ovarian cancer: G-band, FISH, and molecular studies. Cancer Genet Cytogenet 1996; 87: 55-62.
12. Deng X, Ewton DZ, Friedman E,. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by decreasing ROS levels. Cancer Res 2009; 69: 3317-24.
13. Hu J, Friedman E,. Depleting Mirk kinase increases cisplatin toxicity in ovarian cancer cells. Genes Cancer 2010; 1: 803-11.
14. Ewton D, Hu J, Vilenchik M, et al. Inactivation of Mirk/dyrk1b kinase targets quiescent pancreatic cancer cells. Mol Cancer Ther 2011; 10: 2104-14.
15. Litovchick L, Florens LA, Swanson SK, et al. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev 2011; 25: 801-13.
16. Zou Y, Ewton D, Deng D, et al. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem 2004; 279: 27790-8.
17. Deng X, Ewton DZ, Pawlikowski B, et al. Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation. J Biol Chem 2003; 278: 41347-54.
18. Deng X, Mercer SE, Shah S, et al. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G0 by Mirk/dyrk1B kinase. J Biol Chem 2004; 279: 22498-504.
19. D'Andrilli G, Kumar C, Scambia G, et al. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 2004; 10: 8132-41.
20. Fang X, Jin X, Xu HJ, et al. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 1998; 16: 1-8.
21. Flak MB, Connell CM, Chelala C, et al. p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Mol Cancer 2010; 9: 175.
22. Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475: 231-4.
23. Bonner WM, Redon CE, Dickey JS, et al. γ-H2AX and cancer. Nat Rev Cancer 2008; 8: 957-67.
24. Friedman E,. Mirk/dyrk1B in cancer. J Cell Biochem 2007; 102, 274-9.
25. Yang C, Ji D, Weinstein EJ, et al. The kinase Mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis 2009; 31: 552-8.
26. Friedman E,. The kinase Mirk/dyrk1B: a possible therapeutic target in pancreatic cancer. Cancers 2010; 2: 1492-512.
27. Zou Y, Lim S, Lee K, et al. Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial cell migration and is negatively regulated by the Met adaptor Ran-binding protein M. J Biol Chem 2003; 278: 49573-81.
28. Ritterhoff S, Farah CM, Grabitzki J, et al. The WD40-repeat protein Han11 functions as a scaffold protein to control HIPK2 and MEKK1 kinase functions. EMBO J 2010; 29: 3750-61.
29. Leder S, Czajkowska H, Maenz B, et al. Alternative splicing variants of the protein kinase DYRK1B exhibit distinct patterns of expression and functional properties. Biochem J 2003; 372: 881-8.
30. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.